Imatinib mesylate has considerably changed the management of chronic myeloid leukemia (CML) in the chronic phase and has increased the rates of complete cytogenetic remission (CCR) 1 and major molecular remission. 2 Although it has few toxic effects, unusual side effects have been observed such as the appearance of gray hair during treatment. 3 In 2003, the first case of Epstein-Barr Virus (EBV)-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate therapy was reported. 4 We report a case of disseminated EBV-positive lymphoproliferative disease with no correction when imatinib was discontinued, multiple relapses and resistance to rituximab.
A 59-year-old woman was treated with imatinib mesylate (400 mg/day) for chronic phase CML in April 2003. Complete hematological response was achieved after 1 month, CCR after 6 months and complete molecular response (CMR) after 2 years. After 30 months of imatinib mesylate treatment, the patient was still in CMR but suddenly exhibited a decrease in performance status with fever, night sweats, pancytopenia and disseminated intravascular coagulation. She was receiving her usual medication including inhaled beta-2 agonist and inhaled cortisone, since she had a history of asthma. Clinical examination revealed no adenomegaly but there was a huge hepatomegaly (26 cm) and splenomegaly (19.5 cm) confirmed by CT scan. Bone marrow biopsy revealed EBV-positive lymphoproliferative disease characterized by a granulomatous infiltrate containing large immunoblastic cells with pro-eminent nucleoli. Immunostaining showed that these neoplastic cells were positive for CD30, CD20, CD79a and EBV/LMP1, but negative for CD15. In situ hybridization for Epstein-Barr Virus PNA probe/fluoresceine (EBER) DAKO Y 5200 Denmark (EBV-EBER) sequences was positive on these cells. A liver biopsy confirmed hepatic infiltration by the neoplastic cells. Serum EBV quantification by polymerase chain reaction (PCR) was highly positive with 92.140 DNA copies/mm 3 . Viral serologies were negative for HIV but positive for cytomegalovirus (CMV) and EBV. Lymphocyte count was 1520/mm 3 with normal CD4 þ (1300/mm 3 ) and a low CD8 þ subpopulation (122/mm 3 ). Since discontinuation of imatinib for 17 days did not improve the patient's performance status or cytopenia, intravenous rituximab 375 mg/m 2 was given weekly for 4 weeks. After two rituximab injections, clinical remission was observed and EBV quantification was negative (o500 copies of EBV/mm 3 ). One month after the rituximab therapy, a complete response persisted with negative EBV quantification, so imatinib mesylate was reintroduced.
The first relapse was observed 4 months after reintroduction of imatinib with hepatomegaly, splenomegaly and positive EBV quantification but negative BCR-ABL quantification. CD8 þ lymphopenia was again present. After four weekly injections of rituximab, a second clinical and biological complete response was obtained.
The second relapse occurred 6 months later, even though the patient was not receiving imatinib mesylate. Biopsy of the adenomegaly demonstrated EBV-positive lymphoproliferation with large CD79a-positive, CD20-negative and EBER-positive cells (Figure 1a and b). Fluorescence in situ hybridization (FISH) analysis showed a tetrasomy for both BCR and ABL loci without BCR-ABL rearrangement ( Figure 2 ). Bone marrow aspiration revealed a macrophage activation syndrome without lymphoproliferative infiltration. EBV quantification was again positive, as was BCR-ABL quantification, and CD8 þ lymphocyte count had decreased (150/mm 3 ). Since two weekly injections of rituximab were without clinical or biological effect, we initiated chemotherapy in association with interferonalpha. A first cycle of CHOP (cyclophosphamide-vincristinedoxorubicin and prednisolone) associated with a 3MUI subcutaneous injection of interferon-alpha three times per week rapidly led to a complete clinical and biological response. After 3 months of interferon-alpha treatment, the patient was again in CMR ( Figure 3 ).
EBV-associated lymphoid proliferation occurs in the setting of immunosuppression. The level of T-cell depletion is considered to be one of the most important risk factors. 5 In our case, the patient had no history of known immunodeficiency and the a b 
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immunoglobulin level was normal. She presented CD8 þ lymphopenia and was not receiving any systemic immunosuppressor, except that she had been treated with imatinib mesylate for 2 years. In Blood (December 2003), 4 Dr Bekkenk described a case of EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate treatment that spontaneously resolved after discontinuing the treatment and normalizing the leukocyte count. In our patient, imatinib discontinuation failed to induce any change in the leukocyte count or the lymphoproliferative disease, while treatment with rituximab alone resulted in a complete clinical and biological response. The first relapse occurred 4 months after the reintroduction of imatinib mesylate again with CD8 þ lymphopenia and a second complete remission was achieved after the reintroduction of rituximab. However, at the second relapse, the disease progressed to a CD20-negative diffuse large B-cell lymphoma and became rituximab-resistant. Nevertheless, the lymphoproliferative disease remained responsive to conventional chemotherapy with CHOP.
Imatinib mesylate has modified the evolution of CML, 2 leading to an improvement in overall survival and its use as first-line treatment. In vitro studies have shown that imatinib mesylate inhibits the proliferation and activation of T cells and significantly reduces the antigen-triggered expansion of CD8 þ T cells in response to immunodominant CMV and EBV peptides. 6 We speculate that such an effect might have occurred in our patient. During the diagnosis and relapses, her CD8 þ lymphocyte rate was decreased. Our attempt to generate an EBV-positive B-cell line failed and it was not possible to evaluate the specific anti-EBV activity of T cells with or without imatinib. Other as yet unknown causes might have existed in our patient. Indeed, although a growing number of patients is receiving this tyrosine kinase inhibitor, case reports of EBV-positive lymphoproliferative disease remain rare. Essential thrombocytosis (ET) is a hematopoietic stem cell disorder characterized uniquely by the overproduction of platelets in the absence of a definable stimulus. Approximately 50% of ET patients express a mutation of the Janus-associated kinase 2 gene (JAK2 V617F). 1 These patients also appeared to have a 'polycythemia vera (PV)-like' phenotype compared to their JAK2 V617F-negative counterparts.
2 However, quantitative analysis of the neutrophil JAK2 V617F allelic burden indicated that ET patients generally have a lower neutrophil JAK2 V617F allele percentage than JAK2 V617F-positive PV or idiopathic myelofibrosis (IMF) patients. 3, 4 We, therefore, studied 80 consecutive ET patients to determine whether the quantitative neutrophil JAK2 V617F allele burden in ET is correlated with gender, disease presentation, disease evolution or vascular complications. Patients were prospectively enrolled between 2005 and 2006; blood samples were obtained at the time of clinical assessment, and quantitative JAK2 V617F allele percentages were measured from neutrophil genomic DNA or platelet cDNA, as described previously.
3 Median disease duration at the time of phenotypic and genotypic analysis for the entire cohort was 6 years (range 0.5-26 years). Similar to studies with equivalent JAK2 V617F assay sensitivity, 1,5 47% of our patients were JAK2 V617F-positive. Also in keeping with other observations, JAK2 V617F-positive patients were significantly older at diagnosis than JAK2 V617F-negative patients (59 versus 38 years, Pp0.001).
1 Median disease duration of the JAK2 V617F-positive ET patients was also significantly shorter than the JAK2 V617F-negative patients (3 versus 8 years, respectively; P ¼ 0.022), although the ranges were similar (Table 1a) . JAK2 V617F mutation status also did not correlate with hydroxyurea, anagrelide or interferon-a use (Table 1) . While the median hemoglobin concentration was higher in the JAK2 V617-positive group, this did not reach statistical significance when controlled for gender. Similarly, there was no significant difference in the white cell count or platelet count between JAK2 V617-positive and negative patients, nor was there any correlation with a family history of a myelo-proliferative disorder (MPD), which was present in nine JAK2 V617F-positive patients (two male, seven female) and six JAK2 V617F-negative patients (three male, three female).
In the 37 JAK2 V617F-positive ET patients in the present study, the median neutrophil allele percentage was 43% (range 11-64%). The JAK2 V617F allele percentage was not a function of disease duration, since patients early on or decades into their disease had varied allele percentages (Figure 1a) . However, when stratified by gender, we found that women had significantly lower neutrophil JAK2 V617F allele percentages compared to men, regardless of disease duration (36 versus 46%, P ¼ 0.016). We also measured the JAK2 V617F allele burden simultaneously in neutrophil genomic DNA and platelet cDNA from the same blood sample in 27 patients and found that the median neutrophil JAK2 V617F allele percentage (16.0%) was lower than the median platelet allele percentage (38.5%) (Po0.001). When Table 1a Epidemiological and clinical data in 80 ET patients
